Related Experiment Video
Updated: Jan 30, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Precision oncology: as much expectations as limitations
Vitor Fiorin Vasconcellos1, Leandro Machado Colli2, Ahmad Awada3
1Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Abstract:
It is encouraging to witness the recent price reduction and expanded access to next generation sequencing platforms, the increasing number of investments and publications on new targets and respective targeted drugs, as well as the worldwide excitement with anti-cancer personalised therapies. This editorial aims to highlight the limitations regarding the small proportion of solid cancers potentially eligible for the use of molecular-based targeted drugs until now. It also covers the expected clinical benefits in refractory patients treated by matched therapies, and detailed cost-effectiveness analysis of the use of DNA sequencing analysis oncology practice in an academic and large-scale community.
Insights
Next-generation sequencing (NGS) advances personalized cancer therapy. However, only a small fraction of solid tumors are currently eligible for targeted drugs, despite clinical benefits and cost-effectiveness analyses.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Recent advancements in next-generation sequencing (NGS) platforms have led to reduced costs and increased accessibility.
- There is growing investment and research into novel cancer targets and corresponding targeted therapies.
- Personalized anti-cancer therapies are generating significant global interest.
Related Concept Videos
The Precise Definition of a Limit
Expected Value
Limiting Reactant
Determination of Expected Frequency
The Number e as a Limit
Uncertainty in Measurement: Accuracy and Precision

